References
- Attallah AM, Omran D, Marie MS. IL-28B rs12979860 polymorphism affect the course of chronic hepatitis and the development of HCC in Egyptian patients with hepatitis C type 4. Br J Biomed Sci. 2018;75:157–162.
- Arafa M, Besheer T, El-Eraky AM. Genetic variants of XRCC1 and risk of hepatocellular carcinoma in chronic hepatitis C patients. Br J Biomed Sci. 2019;76:64–69.
- Lorente L, Rodriguez ST, Sanz P, et al. Association between pre-transplant serum malondialdehyde levels and survival one year after liver transplantation for hepatocellular carcinoma. Int J Mol Sci. 2016;17:500.
- Marnett LJ. Lipid peroxidation-DNA damage by malondialdehyde. Mutat Res. 1999;424:83–95.
- Hashimoto K, Ikeda Y, Korenaga D, et al. The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer. 2005;103:1856–1864.
- Shiha G, Elagroudy O, Shef S, et al. MicroRNA 122 as a diagnostic biomarker for hepatitis C- related hepatocellular carcinoma. Med J Viral Hepatitis.2019;4:35–43.
- Elsaadawy S, Elbadawy R, Abd Elaziz B, et al. The effect of melatonin on apoptosis in hepatocellular carcinoma cell line: an experimental study. Med J Viral Hepatitis.2019;4:75–79.
- Abdel-Razik A, Mousa N, Rania Elhelaly R, et al. De-novo portal vein thrombosis in liver cirrhosis: risk factors and correlation with the model for end-stage liver disease scoring system. Eur J Gastroenterol Hepatol. 2015;27:585–592.
- Alfar M, Abd El-Maksoud M, Mousa N. B-cell monoclonal lymphocytosis in chronic hepatitis C virus infection. Med J Viral Hepatitis. 2018;3:27–35.
- Czeczot H, Scibior D, Skrzycki M, et al. Glutathione and GSH-dependent enzymes in patients with liver cirrhosis and hepatocellular carcinoma. Acta Biochim Pol. 2006;53:237–241.
- Elalfy H, Besheer T, El-Maksoud M, et al. Monocyte/granulocyte to lymphocyte ratio and the MELD score as predictors for early recurrence of hepatocellular carcinoma after trans-arterial chemoembolization. Br J Biomed Sci. 2018;75:187–191.
- Lin ZY, Wang LY, Yu ML, et al. Role of serum C-reactive protein as a marker of hepatocellular carcinoma in patients with cirrhosis. J Gastroenterol Hepatol. 2000;15:417–421.
- O’Hanlon DM, Lynch J, Cormican M, et al. The acute phase response in breast carcinoma. Anticancer Res. 2002 Mar–Apr;22(2B);221289–221293.
- Alexandrakis MG, Passam FH, Moschandrea IA, et al. Levels of serum cytokines and acute phase proteins in patients with essential and cancer-related thrombocytosis. Am J Clin Oncol. 2003;26:135–140.
- Jabs WJ, Busse M, Kruger S, et al. Expression of C-reactive protein by renal cell carcinomas and unaffected surrounding renal tissue. Kidney Int. 2005;68:2103–2110.